Get the app
US › Healthcare

Vanda Pharmaceuticals Inc (VNDA)

US · Healthcare · Biotechnology

$5.11+2.20%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$50.5M
Revenue YoY
-3.9%
Net profit
$-62.5M
EPS
$-1.04
EPS estimate
$-0.51
Net margin
-123.7%

EPS came in at -1.04 against a street estimate of -0.51 — a miss of 103.9%.

Key statistics

Market cap
$307.8M
Forward P/E
103.1
P/B
1.38
Book value
$4.67
EPS (TTM)
$-4.69
52-week high
$9.94
52-week low
$4.27
50-day MA
$5.46
200-day MA
$6.58
Beta
0.65

Analyst view

Analysts rate Vanda Pharmaceuticals Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $12.19.

Shareholding

Insiders
6.61%
Institutions
86.30%

Largest institutional holders

FundStake
BlackRock Inc12.03%
Renaissance Technologies Corp6.22%
State Street Corp4.99%
Vanguard Capital Management, LLC4.10%
AIGH Capital Management, LLC3.38%
Acadian Asset Management LLC2.97%
Dimensional Fund Advisors, Inc.2.86%
AQR Capital Management LLC2.65%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vanda Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.